Pharmaceutical supply chain security: Combating counterfeit drugs

The recently enacted Drug Quality and Security Act establishes a national track and trace program targeting counterfeit medicines. The new law – to be phased in over 10 years – is expected to cost drugmakers $10 million to $50 million. For now, manufacturers should focus on the requirements set to take effect in 2015 and 2017.

What are the implications?

Younger consumers are more concerned about the safety and quality of their medications
Share this Twitter Linkedin Facebook

Implications of the pharmaceutical supply chain legislation:

  • Drugmakers must work closely with distributors and develop an open dialogue with regulators to guide and monitor changing requirements.
  • Companies should develop a global strategy with local application to meet national and international mandates.
  • Executive-led governance structures and strong program management teams are required to meet evolving regulations.